A Neutral Trial That Should Change Guidelines: CAAN-AF

20 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Join John Mandrola, MD, and Prash Sanders, MBBS, PhD, as they dissect the surprising findings of the CAN AF trial, a crucial study examining the role of AV node ablation in patients with permanent atrial fibrillation (AF) and a CRT device. For years, guidelines suggested AV node ablation was necessary for effective CRT pacing, but this randomized trial challenges that conventional wisdom. Learn why the study found no difference in outcomes, and what this means for current medical practice and future guideline recommendations for patients needing high-percentage bi-ventricular (BiV) pacing

00:00 - Introduction to the CAN AF Trial
00:37 - The Conventional Wisdom on AV Node Ablation and CRT
01:34 - Expectations vs. Results: The Surprising Finding of No Difference
02:16 - Analyzing the Guideline Recommendations (Level 2a)
03:17 - Why AV Node Ablation Was Expected to Be Superior
04:23 - The Futility Analysis: Why the Trial Was Stopped Early
06:46 - Impact on Current Guidelines for BiV Pacing Percentage
08:46 - Conclusion and Takeaway

https://www.medscape.com/viewarticle/neutral-trial-should-change-guidelines-caan-af-2025a1000rkb

#CANAFTrial #AVNodeAblation #CRTPacing #AtrialFibrillation #AFibTreatment #CardiacResynchronizationTherapy #BiventricularPacing #Cardiology
Categoria
Cardiology
Commenta per primo questo video.

Prossimo